96187-53-0
基本信息
布喹钠
BREQUINAR 布喹那
6-氟-2-(2'-氟-[1,1'-联苯]-4-基)-3-甲基喹啉-4-羧酸
DIHYDROOROTATE DEHYDROGENASE抑制剂(BREQUINAR)
CS-157
Brequinar
Biphenquinate
Brequinar (DUP785)
BREQUINAR
BIPENQUINATE
DUP 785
NSC 368390.
6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)
6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-Methylquinoline-4-carboxyl
6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid
6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid
物理化学性质
| 熔点 | 355-357℃ (N,N-dimethylformamide water ) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO:25.9(Max Conc. mg/mL);70.0(Max Conc. mM) |
| 酸度系数(pKa) | pKa 4.45(H2O t=RT I=0.10) (Uncertain) |
| 形态 | 粉末晶体 |
| 颜色 | 白色至浅黄色 |
| CAS 数据库 | 96187-53-0 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P305+P351+P338 |
| 海关编码 | 2933.49.7000 |
布喹那价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/08/19 | HY-108325 | 布喹那 Brequinar | 96187-53-0 | 5mg | 700元 |
| 2024/08/19 | S6626 | 布喹那 Brequinar (DUP785) | 96187-53-0 | 5mg | 794.84元 |
| 2024/08/19 | HY-108325 | 布喹那 Brequinar | 96187-53-0 | 10mM * 1mLin DMSO | 770元 |
常见问题列表
| Target | Value |
|
DHODH
() | 20 nM |
Brequinar reduces virus progeny production by >90%, with EC 50 of 17 nM. Brequinar (5 μM) also inhibits other orthopoxviruses, and blocks virus DNA replication. Brequinar does not affect virus early gene expression, but has a severe effect on the late stage of the virus cycle. Brequinar reduces the level of envelope protein production and the viral titer in a dose-dependent manner, with EC 50 of 78 nM in the CFI assay. Brequinar (5 μM) inhibits viral RNA synthesis. Brequinar has antiviral effect, but the effect is reversed by pyrimidine. Brequinar-resistant viruses can be selected in cell culture. Brequinar (5 μM) suppresses the luciferase activities from both the WT and NS5 mutant replicons. Brequinar sodium effectively prevents the increase in PyNTP levels with an IC 50 of 0.26 μM. Brequinar sodium effectively inhibits cell proliferation with an IC 50 of 0.26 μM. Brequinar sodium inhibits autophosphorylation of p56 lck with IC 50 of 70 μM; inhibition is 39, 41, and 60% for 25, 50, and 100 μM Brequinar sodium, respectively. Brequinar sodium also inhibits the phosphorylation by p56 lck of the exogenous substrate, histone 2B, with an IC 50 of 70 μM; inhibition is 10, 43, 59, and 86% for 25, 50, 100, and 200 μM Brequinar sodium, respectively. Brequinar sodium inhibits autophosphorylation of p59 fyn with an IC 50 of 105 μM; inhibition is 0, 17, 48, and 65% for 25, 50, 100, and 200 μM Brequinar sodium, respectively. Brequinar sodium also inhibits the phosphorylation by p59 fyn of histone 2B with an IC 50 of 20 μM; inhibition is 26, 54, 79, 83, and 84% for 10, 25, 50, 100, and 200 μM Brequinar sodium, respectively.
Brequinar sodium-treated (10-20 mg/kg/day) mice has a 31% reduction in percentage of packed cell volume compared with untreated BALB/c mice. Brequinar sodium reduces UTP and CTP levels in bone marrow cells by 30 and 25%, respectively. Brequinar sodium (10-20 mg/kg/day) in combination with uridine (1000-2000 mg/kg/day) prevents anemia, and the hematocrits remain at levels (61-63%) comparable with those of untreated controls.